These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20139095)

  • 1. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
    Xuan C; Steward KK; Timmerman JM; Morrison SL
    Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.
    Trinh KR; Vasuthasawat A; Steward KK; Yamada RE; Timmerman JM; Morrison SL
    J Immunother; 2013 Jun; 36(5):305-18. PubMed ID: 23719241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
    Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
    Blood; 2009 Oct; 114(18):3864-71. PubMed ID: 19710501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
    Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
    MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
    Huang TH; Chintalacharuvu KR; Morrison SL
    J Immunol; 2007 Nov; 179(10):6881-8. PubMed ID: 17982079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
    Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
    Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
    Li B; Zhao L; Guo H; Wang C; Zhang X; Wu L; Chen L; Tong Q; Qian W; Wang H; Guo Y
    Blood; 2009 Dec; 114(24):5007-15. PubMed ID: 19828699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.
    Liao J; Luan Y; Ren Z; Liu X; Xue D; Xu H; Sun Z; Yang K; Peng H; Fu YX
    Cancer Immunol Res; 2017 Jul; 5(7):560-570. PubMed ID: 28533311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
    Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
    Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes.
    Golay J; Cittera E; Di Gaetano N; Manganini M; Mosca M; Nebuloni M; van Rooijen N; Vago L; Introna M
    Haematologica; 2006 Feb; 91(2):176-83. PubMed ID: 16461301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies
    Qin H; Wei G; Sakamaki I; Dong Z; Cheng WA; Smith DL; Wen F; Sun H; Kim K; Cha S; Bover L; Neelapu SS; Kwak LW
    Clin Cancer Res; 2018 Mar; 24(5):1114-1123. PubMed ID: 29180606
    [No Abstract]   [Full Text] [Related]  

  • 16. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
    Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
    Bornstein GG; Quéva C; Tabrizi M; van Abbema A; Chavez C; Wang P; Foord O; Ahluwalia K; Laing N; Raja S; Wen S; Green LL; Yang X; Webster C; Stewart R; Blakey D
    Invest New Drugs; 2010 Oct; 28(5):561-74. PubMed ID: 19626278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
    Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
    J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
    Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
    Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
    Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
    Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.